HYDERABAD: Pharma major Dr Reddy’s Laboratories on Saturday said its active pharmaceutical ingredients manufacturing facility at Middleburgh in New York has been issued a Form 483 with two observations by the US drug regulator, US Food and Drug Administration (US FDA).
“We have been issued a Form 483 with two observations, which we will address within the stipulated timeline,” Dr Reddy’s said in a regulatory filing .
The Hyderabad-based company said the good manufacturing practices (GMP) inspection was conducted by US FDA between May 12, 2025, and May 16, 2025, the company said.
A Form 483 is issued by USFDA inspectors to the management of the company at the end of an onsite inspection if inspectors find any violations of the Food, Drug and Cosmetic (FD&C) Act or other regulations, as per USFDA.
“We have been issued a Form 483 with two observations, which we will address within the stipulated timeline,” Dr Reddy’s said in a regulatory filing .
The Hyderabad-based company said the good manufacturing practices (GMP) inspection was conducted by US FDA between May 12, 2025, and May 16, 2025, the company said.
A Form 483 is issued by USFDA inspectors to the management of the company at the end of an onsite inspection if inspectors find any violations of the Food, Drug and Cosmetic (FD&C) Act or other regulations, as per USFDA.
You may also like
Helping students make right choice: DGCA directs flying schools to display data on website
Pep Guardiola and Dean Henderson in furious row after Crystal Palace beat Man City
Drinking Water Shortage; Villagers Protest With Empty Vessels In Diglai Village Of Mandu
Brace yourselves: Keir Starmer special set to rear ugly head to fury of ordinary Brits
Britain's Got Talent star unrecognisable seven years after audition stunned viewers
